The U.S. Food and Drug Administration (FDA) expanded the approval on Oct. 15 of the Edwards Lifesciences’ SAPIEN XT transcatheter heart valve for aortic valve-in-valve procedures.

The expanded approval comes from the one-year outcomes of the PARTNER II Valve-in-Valve Registry trial, presented Oct. 15 at TCT 2015. The results showed that Valve-in-valve transcatheter aortic valve replacement (TAVR) may be a beneficial therapeutic alternative to reoperation in patients with failed aortic bioprostheses.

Read more from the FDA about the SAPIEN XT device.

Keywords: Aortic Valve, Aortic Valve Stenosis, Bioprosthesis, Heart Valves, Registries, Reoperation, Transcatheter Aortic Valve Replacement, United States Food and Drug Administration

< Back to Listings